Nanobiotix

NBTX

Market cap $1.23B

As of Oct. 2, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Data presented at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on October 1 st

PARIS and CAMBRIDGE, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and announced its half year financial results for the six-month period ended June 30, 2025.

Data presented as a “Top-rated Abstract in Head and Neck Cancer” at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on September 29th

Nanobiotix SA NBTX announced new results focused on patients with primary cutaneous melanoma from an ongoing Phase 1 Study.

Nanobiotix S.A. stock has surged after strong Phase 1 data for NBTXR3 in anti-PD-1 resistant melanoma, showing high response and disease control rates. NBTX's partnership with Janssen could yield up to $2.6bn in milestones, crucial for funding late-stage trials and extending financial runway. Upcoming catalysts include Phase 3 head and neck cancer data and NSCLC trial progress, with a $10bn market opportunity if approved.

Nanobiotix S.A. - Special Call Company Participants Joanne Choi Laurent Levy - Co-Founder, President of the Executive Board & CEO Conference Call Participants Ruoxi Liao - Guggenheim Securities, LLC, Research Division Clemence Thiers - Stifel, Nicolaus & Company, Incorporated, Research Division Swayampakula Ramakanth - H.C.

Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1 Recommended phase 2 dose (RP2D) established at 33% of gross tumor volume (GTV) 47.4% (9/19) best observed objective response rate (ORR) in all lesions per RECIST 1.1 78.9% (15/19) best observed disease control rate (DCR) in all lesions per RECIST 1.1 14.6 months median Overall Survival (mOS) in all patients treated (n=21) Investigators concluded that these data warrant further investigation in randomized clinical trials as a potential new option for patients with primary cutaneous melanoma naïve or refractory to anti-PD-1 Nanobiotix will host a conference call to discuss the data on September 18, 2025 at 8:00AM EDT/ 2:00PM CEST Data presented on September 17 at the 2025 Immunorad Conference PARIS and CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced new results focused on patients with primary cutaneous melanoma from the ongoing Phase 1 Study 1100 evaluating JNJ-1900 (NBTXR3) in combination with immune checkpoint inhibitors (pembrolizumab or nivolumab) for patients with advanced cancers.

PARIS and CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in a fireside chat at following conference:

PARIS and CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''),  a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced two important developments that aim to reinforce the global positioning of potential first-in-class radioenhancer JNJ-1900 (NBTXR3), which is licensed by Janssen Pharmaceutica NV, a Johnson & Johnson company.